Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 63

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 63
---
 the first anniversary of the commencement of his employment and was paid in 2024. The Relocation Bonus is subject to repayment if Mr. McFarlane resigns for any reason (other than for “good reason,” as defined in Mr. McFarlane’s employment agreement) or is terminated for “cause” (as defined in Mr. McFarlane’s employment agreement), in either case, within two years after the commencement of his employment. Upon a termination of Mr. McFarlane’s employment without cause by the Company or resignation for good reason, Mr. McFarlane is entitled to receive (a) an amount of cash equal to 1.0 times his annual base salary, (b) a pro-ratedtarget annual bonus for the year in which termination occurs, (c) twelve months of Company-paidCOBRA continuation coverage, and (d) full vesting of his outstanding and unvested equity awards. However, if any such termination occurs within one month prior to or six months after a change in control, he will instead receive (a) an amount of cash equal to 1.5 times his annual base salary, (b) a target annual bonus for the year in which termination occurs, (c) eighteen months of Company-paidCOBRA continuation coverage, and (d) full vesting of his outstanding and unvested equity awards. Upon Mr. McFarlane’s termination due to death or disability, Mr. McFarlane will receive a pro-ratedtarget annual bonus. Mr. McFarlane is also subject to 12-month post-termination non-competitionand non-solicitationrestrictions. Adrian Quartel, M.D., PPFM In January 2024, we entered into an employment agreement with Dr. Quartel under which he serves as our Chief Medical Officer (the “Quartel Agreement”). Pursuant to the Quartel Agreement, Dr. Quartel is entitled to (i) an initial annual base salary of $485,000, (ii) an annual performance-basedtarget bonus of 40% of his annual base salary and (iii) an initial award of an option to purchase 300,000 shares of the Company’s common stock, which was granted to him in January 2024. Upon a termination of Dr. Quartel’s employment without cause by the Company or resignation for good reason, Dr. Quartel is entitled to receive (a) an amount equal to 12 months of his annual base salary, less applicable deductions, payable in accordance with our